within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EB04_Osimertinib;

model Osimertinib
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.7,
    Cl = 3.944444444444444e-06,
    adminDuration = 600,
    adminMass = 80 / 1000000,
    adminCount = 1,
    Vd = 0.918,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0009,
    Tlag = 1020,
    Vdp = 2.06,
    k12 = 1.0055555555555557e-05,
    k21 = 1.0055555555555557e-05);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Osimertinib</td></tr><tr><td>ATC code:</td><td>L01EB04</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>80</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>918</td><td>L</td></tr>
    <tr><td>clearance:</td><td>14.2</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Osimertinib is a third-generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor indicated for the treatment of non-small cell lung cancer (NSCLC) with specific EGFR mutations, including T790M mutation-positive NSCLC. It is currently approved and widely used for this purpose.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters of osimertinib in adult patients with advanced EGFR T790M mutation-positive NSCLC after oral administration.</p><h4>References</h4><ol><li><p>Tsutani, Y, et al., &amp; He, J (2023). Adjuvant Osimertinib vs. Placebo in Completely Resected Stage IA2-IA3 EGFR-Mutated NSCLC: ADAURA2. <i>Clinical lung cancer</i> 24(4) 376–380. DOI:<a href=\"https://doi.org/10.1016/j.cllc.2023.02.002\">10.1016/j.cllc.2023.02.002</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/36872181/\">https://pubmed.ncbi.nlm.nih.gov/36872181</a></p></li><li><p>Johnson, M, et al., &amp; Vishwanathan, K (2025). Population Pharmacokinetics of Osimertinib in Patients With Non-Small Cell Lung Cancer. <i>Pharmacology research &amp; perspectives</i> 13(3) e70098–None. DOI:<a href=\"https://doi.org/10.1002/prp2.70098\">10.1002/prp2.70098</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/40289712/\">https://pubmed.ncbi.nlm.nih.gov/40289712</a></p></li><li><p>Ballard, P, et al., &amp; Cross, D (2016). Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity. <i>Clinical cancer research : an official journal of the American Association for Cancer Research</i> 22(20) 5130–5140. DOI:<a href=\"https://doi.org/10.1158/1078-0432.CCR-16-0399\">10.1158/1078-0432.CCR-16-0399</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27435396/\">https://pubmed.ncbi.nlm.nih.gov/27435396</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.L.L01EB04 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Osimertinib;
